Imatinib resistance due to a novel and rare class of mutation at position S348 (1043nt C →A) of Bcr/Abl gene in a chronic myeloid leukemia patient
The chronic myeloid leukemia (CML) occurs due to t(9;22)(q34;q22.1) molecularly Bcr/Abl fusion gene. Imatinib mesylate (IM), the molecular targeted drug for the treatment of all phases of CML is a 2-phenylaminopyrimidine derivative that works by binding to the tyrosine kinase domain of Bcr-Abl and blocking its function [1,2]. Targeted inhibition of Bcr-Abl kinase with IM has become the frontline therapy for newly diagnosed CML patients [3]. Despite the successful treatment results obtained with IM, achievement of prolonged response to IM is still a challenging problem and a significant number of patients develop resistance to IM.
Source: Leukemia Research - Category: Hematology Authors: Somprakash Dhangar, Selvaa Kumar C, Chandrakala S, Babu Rao Vundinti Tags: Letter to the Editor Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Genetics | Gleevec | Hematology | Leukemia